Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861598 · ClinicalTrials.gov registry record · Early Phase 1
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
A Early Phase 1 study, sponsored by West Virginia University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT03861598 is a Early Phase 1 study that was terminated before completion, run by West Virginia University. The registered enrollment target is 4 participants.
The verdict
NCT03861598, a Early Phase 1 study, was terminated before completion, sponsored by West Virginia University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also receive Carvedilol for 4 cycles of treatment. Carvedilol will start at 6.25 mg orally twice a day and be increased to 12.5 mg orally twice daily after 1 to 2 weeks if tolerated. Peripheral glioma circulating tumor cells (CTC) and brain MRI with and without contrast will be obtained at baseline, 2 cycles, and 4 cycles to determine the efficacy and direction of change of the CTC using a new assay tool. Preliminary assessment of the tolerability of Carvedilol with standard chemotherapy will also be evaluated.
Interventions
- DRUG Carvedilol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2021-06-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861598
The ClinicalTrials.gov registry entry for NCT03861598 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carvedilol is the first listed.
NCT03861598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03861598 about?
NCT03861598 is a clinical study titled "Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells". Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also receive Carvedilol for 4 cycles of treatment. Carvedilol will start at 6.25 mg orally twice a day and be increased to 12.5 mg orally twice daily after 1 to 2 weeks if tolerated. Peripheral glioma circulatin...
What is the current status of trial NCT03861598?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2019-07-19. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT03861598?
The interventions under investigation include: Carvedilol (DRUG).
Who is sponsoring clinical trial NCT03861598?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.